Tina Ko1, Claire Dendle2,3, Ian Woolley2,3, Eric Morand1,3, Anna Antony1,3. 1. Department of Rheumatology, Monash Health, Clayton, Australia. 2. Department of Infectious Diseases, Monash Health, Clayton, Australia. 3. School of Clinical Sciences, Monash University, Clayton, Australia.
Abstract
OBJECTIVES: To evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine acceptance among patients with rheumatic diseases (RMD). METHODS: All rheumatology patients attending a large suburban health network were invited to participate in an anonymized online survey. The primary outcome of interest was SARS-COV-2 vaccine acceptance. RESULTS: The mean (SD) age of respondents (n = 641) was 52.7 (15.1) years and 74.4% (n = 474) were female. Sixty-five percent were willing to have a SARS-COV-2 vaccine, while 34.4% were vaccine-hesitant (unwilling or undecided). On multivariate analysis, vaccine acceptance was associated with smoking (OR: 2.25 [95% CI: 1.22-4.15; p = .009]), history of malignancy (OR: 2.51 [95% CI: 1.19-5.26; p = .015]), influenza or pneumococcal vaccination in the preceding year (OR: 2.69 [95% CI: 1.78-4.05; p < .001]) and number of COVID-Safe measures practiced (OR: 1.54 [95% CI: 1.05-2.26; p = .027]). Vaccine acceptance correlated with positive beliefs regarding vaccine efficacy (r = 0.40; p < .001) and safety (r = 0.36; p < .001). Vaccine acceptance correlated negatively with concerns regarding side-effects (r = -0.30; p < .001) and vaccine-associated RMD flare (r = -0.21; p < .001). In vaccine-hesitant respondents, 39.2% were more likely to accept vaccination if given a choice of which vaccine they receive and 54.5% if their rheumatologist recommended it. Twenty-seven percent of patients on immunomodulators were willing to withhold medications while 42.1% were willing if advised by their rheumatologist. CONCLUSION: SARS-COV-2 vaccine hesitancy is prevalent amongst RMD patients and associated with concerns regarding vaccine safety, efficacy, side effects and RMD flare. Clinician recommendation, vaccine choice and communications targeting patient concerns could facilitate vaccine acceptance.Significance and Innovations Vaccine hesitancy is prevalent in RMD patientsVaccine acceptance is associated with beliefs regarding vaccine safety and efficacy and concerns regarding RMD flare and vaccine-associated side effectsVaccine choice and clinician recommendation have the potential to improve vaccine acceptance in patients who are hesitant.
OBJECTIVES: To evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine acceptance among patients with rheumatic diseases (RMD). METHODS: All rheumatology patients attending a large suburban health network were invited to participate in an anonymized online survey. The primary outcome of interest was SARS-COV-2 vaccine acceptance. RESULTS: The mean (SD) age of respondents (n = 641) was 52.7 (15.1) years and 74.4% (n = 474) were female. Sixty-five percent were willing to have a SARS-COV-2 vaccine, while 34.4% were vaccine-hesitant (unwilling or undecided). On multivariate analysis, vaccine acceptance was associated with smoking (OR: 2.25 [95% CI: 1.22-4.15; p = .009]), history of malignancy (OR: 2.51 [95% CI: 1.19-5.26; p = .015]), influenza or pneumococcal vaccination in the preceding year (OR: 2.69 [95% CI: 1.78-4.05; p < .001]) and number of COVID-Safe measures practiced (OR: 1.54 [95% CI: 1.05-2.26; p = .027]). Vaccine acceptance correlated with positive beliefs regarding vaccine efficacy (r = 0.40; p < .001) and safety (r = 0.36; p < .001). Vaccine acceptance correlated negatively with concerns regarding side-effects (r = -0.30; p < .001) and vaccine-associated RMD flare (r = -0.21; p < .001). In vaccine-hesitant respondents, 39.2% were more likely to accept vaccination if given a choice of which vaccine they receive and 54.5% if their rheumatologist recommended it. Twenty-seven percent of patients on immunomodulators were willing to withhold medications while 42.1% were willing if advised by their rheumatologist. CONCLUSION: SARS-COV-2 vaccine hesitancy is prevalent amongst RMD patients and associated with concerns regarding vaccine safety, efficacy, side effects and RMD flare. Clinician recommendation, vaccine choice and communications targeting patient concerns could facilitate vaccine acceptance.Significance and Innovations Vaccine hesitancy is prevalent in RMD patientsVaccine acceptance is associated with beliefs regarding vaccine safety and efficacy and concerns regarding RMD flare and vaccine-associated side effectsVaccine choice and clinician recommendation have the potential to improve vaccine acceptance in patients who are hesitant.
Authors: Jeffrey V Lazarus; Katarzyna Wyka; Lauren Rauh; Kenneth Rabin; Scott Ratzan; Lawrence O Gostin; Heidi J Larson; Ayman El-Mohandes Journal: J Health Commun Date: 2020-10-02
Authors: Caoilfhionn M Connolly; Jake A Ruddy; Brian J Boyarsky; Robin K Avery; William A Werbel; Dorry L Segev; Jacqueline Garonzik-Wang; Julie J Paik Journal: Ann Rheum Dis Date: 2021-03-19 Impact factor: 19.103
Authors: Robert Bm Landewé; Pedro M Machado; Féline Kroon; Hans Wj Bijlsma; Gerd R Burmester; Loreto Carmona; Bernard Combe; Massimo Galli; Laure Gossec; Annamaria Iagnocco; John D Isaacs; Xavier Mariette; Iain McInnes; Ulf Mueller-Ladner; Peter Openshaw; Josef S Smolen; Tanja A Stamm; Dieter Wiek; Hendrik Schulze-Koops Journal: Ann Rheum Dis Date: 2020-06-05 Impact factor: 27.973
Authors: Vasco C Romão; Inês Cordeiro; Carla Macieira; Filipa Oliveira-Ramos; José Carlos Romeu; Carlos Miranda Rosa; Maria João Saavedra; Fernando Saraiva; Elsa Vieira-Sousa; João Eurico Fonseca Journal: RMD Open Date: 2020-06
Authors: Jeffrey V Lazarus; Scott C Ratzan; Adam Palayew; Lawrence O Gostin; Heidi J Larson; Kenneth Rabin; Spencer Kimball; Ayman El-Mohandes Journal: Nat Med Date: 2020-10-20 Impact factor: 53.440
Authors: Laura Boekel; Femke Hooijberg; Yaëlle R Besten; Erik H Vogelzang; Maurice Steenhuis; Maureen Leeuw; Sadaf Atiqi; Ronald van Vollenhoven; Willem F Lems; Wouter H Bos; Carla A Wijbrandts; Martijn Gerritsen; Charlotte Krieckaert; Alexandre E Voskuyl; Irene E van der Horst-Bruinsma; Sander W Tas; Maarten Boers; Theo Rispens; Michael T Nurmohamed; Gertjan Wolbink Journal: Lancet Rheumatol Date: 2022-02-08
Authors: Monica M Yang; Kimberly E Taylor; Diana Paez; Alex Carividi; Emanuel Demissie; Niti Pawar; Alia A El-Qunni; Lily E McMorrow; Rebecca E Schriefer; Katherine Huang; Baylee Kinnett; Michael Klebert; Alem Haile; Jane A O'Halloran; Rachel M Presti; Wooseob Kim; Ali H Ellebedy; Matthew A Ciorba; Michael A Paley; Parakkal Deepak; Alfred H J Kim; Patricia Katz; Mehrdad Matloubian; Mary Nakamura; Lianne S Gensler Journal: Arthritis Care Res (Hoboken) Date: 2022-04-12 Impact factor: 5.178
Authors: Frank Müller; Stephanie Heinemann; Eva Hummers; Eva Maria Noack; Gloria Heesen; Alexandra Dopfer-Jablonka; Marie Mikuteit; Jacqueline Niewolik; Sandra Steffens; Dominik Schröder Journal: Z Rheumatol Date: 2022-05-06 Impact factor: 1.530
Authors: Daphne Day; Lisa Grech; Mike Nguyen; Nathan Bain; Alastair Kwok; Sam Harris; Hieu Chau; Bryan Chan; Richard Blennerhassett; Louise Nott; Nada Hamad; Annette Tognela; David Hoffman; Amelia McCartney; Kate Webber; Jennifer Wong; Craig Underhill; Brett Sillars; Antony Winkel; Mark Savage; Bao Sheng Loe; Daniel Freeman; Eva Segelov Journal: Vaccines (Basel) Date: 2022-05-26